sitefansalaran International News

The NHS has started rolling out a new at-home heart monitor designed to detect heart rhythm problems. Unlike traditional monitors that can require lengthy set-up by a trained physiologist, the innovative kit can be posted to patients for them to attach themselves at home and used to investigate conditions including atrial fibrillation, tachycardia or heart blocks. The device itself is a small patch that adheres to the skin, while traditional devices see patients hooked up to numerous wires and monitors during hospital visits. After the new tool is worn for a few days, patients simply post the monitor back, removing the necessity for appointments to fit and remove the equipment. The collected data is then analysed by an artificial intelligence (AI) tool called Cardiologs, which generates a report for assessment by a physiologist or doctor. Frimley Health NHS Foundation Trust is the first hospital in the country to roll out the device, with hopes that the device will soon be used across other NHS trusts. The Trust said it will still use traditional devices, known as Holter monitors, on some patients who are in hospital, but many of those who are outside of hospital will be able to access the new ePatch, which is made...

Sun Pharma, India’s largest pharmaceutical company by revenue, announced that it has launched its new anti-hair loss medication, Leqselvi (deuruxolitinib), as an 8 mg oral tablet in the U.S. market following the resolution of a patent dispute with Incyte Corporation. Leqselvi is designed for the treatment of severe cases of Alopecia Areata, a chronic autoimmune disorder characterized by patchy hair loss. The drug is now available to patients in the U.S. after receiving regulatory approval, and it can be prescribed by physicians for individuals suffering from the more advanced forms of the condition. According to Sun Pharma's official press release, Leqselvi is a Janus kinase (JAK) inhibitor and represents an important therapeutic option for patients who previously had limited treatment choices. The U.S. FDA approved deuruxolitinib for Alopecia Areata based on clinical trials demonstrating significant hair regrowth in a majority of patients over a 24-week period. Sun Pharma holds the exclusive rights to market the drug in the U.S. under the terms of its agreement with Incyte.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause. When oestrogen levels drop during menopause, certain brain cells become overactive and interrupt the body’s ability to control temperature, which leads to hot flushes and night sweats. Elinzanetant is a new non-hormonal medication which works by calming these signals in the brain, helping bring the body’s temperature control back into balance. It may also help improve sleep problems that often come with menopause. This medicine is administered in capsule form, to be taken orally. Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said: “Hot flushes and night sweats associated with menopause can have a significant negative impact on quality of life. “We are therefore pleased to announce our approval of elinzanetant, which has met the MHRA’s standards for safety, quality and effectiveness. “Elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies. As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.” Elinzanetant’s approval is based...

Nearly a third of U.S. teens are prediabetic, according to new data from the Centers for Disease Control and Prevention. In 2023, a count found that an estimated 8.4 million adolescents between the ages of 12 and 17 – or 32.7 percent – fell into that category. The alarming results are a “wake-up call,” Dr. Christopher Holliday, the agency’s top official in charge of diabetes prevention, said in a statement to ABC News. He said that the risk of type 2 diabetes poses a "significant threat" to young people's health. With prediabetes, a person’s blood sugar levels are higher than normal but not high enough for a type 2 diabetes diagnosis. Having prediabetes increases your risk of developing type 2 diabetes, as well as heart disease and stroke. Diabetes is the seventh leading cause of death in the U.S. Type 2 diabetes is a chronic condition that occurs when the body cannot use the essential hormone insulin, which helps manage blood sugar levels and aids the body in turning food into energy. Problems with insulin often start around puberty, according to Yale Medicine. Without treatment, it can cause kidney disease, stroke, and heart disease. “Simple life changes – like healthy eating and staying active...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause. When oestrogen levels drop during menopause, certain brain cells become overactive and interrupt the body’s ability to control temperature, which leads to hot flushes and night sweats. Elinzanetant is a new non-hormonal medication which works by calming these signals in the brain, helping bring the body’s temperature control back into balance. It may also help improve sleep problems that often come with menopause. This medicine is administered in capsule form, to be taken orally. Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said: “Hot flushes and night sweats associated with menopause can have a significant negative impact on quality of life. “We are therefore pleased to announce our approval of elinzanetant, which has met the MHRA’s standards for safety, quality and effectiveness. “Elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies. As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.” Elinzanetant’s approval is based...

The Global Agency for Responsible AI in Health, today welcomes Singapore as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of AI in healthcare. The agreement signed today marks the start of a collaboration between Singapore’s Ministry of Health (MOH) and HealthAI to share best practices and information aimed at accelerating global efforts for safer and more effective deployment of AI in healthcare, as well as contribute to regulatory solutions such as a “Global Public Directory of AI-related Registered Solutions for Health.” This strengthens Singapore’s position as a leader in the responsible adoption of AI across healthcare and represents a milestone in HealthAI’s objective to foster global collaboration for equitable, safe and effective AI-driven health solutions. The first cohort of ten Pioneer Countries is slated to launch by Q3 2025. Singapore is the first Asian nation to join this inaugural cohort. The signing also reaffirms Singapore’s commitment to improving health outcomes for its own citizens while nurturing a regional ecosystem where neighbouring countries can engage, exchange ideas, and explore opportunities to meaningfully advance the responsible use of AI in healthcare.

The Ambulatory Surgical Center Market is rapidly evolving with a shift toward outpatient surgical procedures due to improvements in surgical technologies and patient preference for cost-effective, accessible care. Increasing demand for minimally invasive surgeries and enhanced recovery protocols continues to propel ASC adoption globally. The Global Ambulatory Surgical Center Market size is estimated to be valued at USD 52.4 billion in 2025 and is expected to reach USD 85.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032. ● In 2024, the average pricing for outpatient surgeries at ambulatory surgical centers was approximately 40-60% lower than inpatient hospital costs, driving wider market acceptance. ● Supply-side indicators highlight a steady increase in ASC facility openings, with the U.S. reporting a 12% YoY growth in new surgical center establishments in 2023 alone. ● Demand-side data shows a 9% rise in outpatient orthopedic and ophthalmology procedures performed in ASCs between 2023-2024, affirming sector-specific growth momentum. ● Import-export flows of advanced surgical tools and diagnostic equipment for ASCs surged by 8.5% in 2024, correlating with expanding surgical capacity globally. ● Micro-level analysis reveals platforms offering bundled payment solutions have improved ASC case volumes by 15% in Q4 2024, reflecting innovative business models...

The European Union aims to stockpile critical medical equipment and vaccines in case of future health crises and to set up a network to ease coordination among EU countries, European crisis chief Hadja Lahbib said on Wednesday. The 27-country bloc is scarred by the memory of the COVID-19 pandemic when it faced a shortage of vaccines and protective masks. "We need a long-term strategy to make sure that essential supplies that keep society running are always available," European Commissioner Lahbib told a news conference. Under the EU Stockpiling and Medical Countermeasures Strategies, the EU will draw up a priority list of medical equipment to be stockpiled in Europe, including vaccines, therapeutics, diagnostics, and personal protective equipment. The EU will double investments in the Health Emergency Preparedness and Response, known as HERA for short, to 200 million euros ($234 million) by 2027, Lahbib said. The scheme funds research and development projects. She said the European Commission will also launch a Medical Countermeasures Accelerator to serve as a one-stop shop to help companies access financing to develop health technologies. A European and Global Wastewater Sentinel System will be set up to collect samples from European airports to detect disease hotspots and monitor in real time the evolution...

Varda Space Industries said on Thursday it has raised $187 million in a funding round led by venture capital firms Natural Capital and Shrug Capital to boost the technology for robotic drug manufacturing in space. The latest round, which included participation from Lux Capital, billionaire Peter Thiel, Founders Fund and Vinod Khosla's eponymous investment fund Khosla Ventures, brings the total capital raised by Varda to $329 million. "With this capital, Varda will continue to increase our flight cadence and build out the pharmaceutical lab that will deliver the world's first microgravity-enabled drug formulation," said Varda CEO Will Bruey. Materials such as active pharmaceutical ingredients in medicines crystallize differently in space due to the lack of gravity, creating drug formulations that would otherwise be impossible, the company said. Its current space vehicles can also be used to mass manufacture drugs in space at a later date, the company said. "When you think about mass manufacturing, it doesn't necessarily mean that we need to like scale up by like 1000x in terms of size of vehicle," said Delian Asparouhov, cofounder of Varda Space Industries. "Our current vehicles can bring back on the order of 50 kilograms of active pharmaceutical ingredient. For the sets of drugs that we're...

End of Marburg! On March 13, 2025, the Ministry of Health of the United Republic of Tanzania officially declared the end of the Marburg virus disease (MVD) outbreak. Officials from the World Health Organization (WHO) African Region stated:Close collaboration with local Tanzanian authorities, along with support from WHO and partners, and the deployment of frontline healthcare teams to protect the population and halt the virus’s spread, were key elements in the response to the outbreak.